Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
20,22-hydroxylumisterol-3 + NADPH + H+
? + NADP+
Substrates: -
Products: -
?
20S-hydroxy-7-dehydrocholesterol + NADPH + H+
20S-hdroxycholesterol + NADP+
Substrates: -
Products: -
?
22-hydroxylumisterol-3 + NADPH + H+
? + NADP+
Substrates: -
Products: -
?
27-hydroxydehydrocholesterol + NADPH + H+
27-hydroxycholesterol + NADP+
Substrates: -
Products: -
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
desmosterol + NADP+
Substrates: -
Products: -
?
7-dehydrositosterol + NADPH
sitosterol + NADP+
-
Substrates: 25% of that with 7-dehydrocholesterol
Products: -
?
7-hydroxycholesterol + NADPH + H+
cholesterol + NADP+
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
cholesta-5,7-dien-3alpha-ol + NADPH
epicholesterol + NADP+
-
Substrates: i.e. 7-dehydroepicholesterol, 25% activity of that with 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-7-en-3beta-ol + NADPH
?
cholesterol + NADP+
cholesta-5,7-dien-3-beta-ol + NADPH + H+
Substrates: -
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-eneol + NADP+
Substrates: -
Products: -
?
ergosta-5,7-dienol + NADPH
ergosta-5-enol + NADP+
ergosterol + NADP+
?
-
Substrates: -
Products: -
r
ergosterol + NADPH + H+
brassicasterol + NADP+
Substrates: -
Products: -
?
lumisterol-3 + NADPH + H+
? + NADP+
Substrates: -
Products: -
?
additional information
?
-
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: -
Products: -
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: terminal step in desmosterol de novo biosynthesis, pathway and physiological role, overview
Products: -
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
Substrates: -
Products: desmosterol is cholesta-5,24-dienol
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
Substrates: -
Products: desmosterol is cholesta-5,24-dienol
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: -
Products: -
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
Substrates: highly regiospecific for DELTA7-bond reduction, but wide substrate specificity
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: defect in cholesterol biosynthesis cause multiple congenital, developmental and morphogenic anomalies, e.g. the Smith-Lemli-Opitz syndrome due to a gene mutation, overview
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: cholesterol formation outside myelin sheath
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: reversibility of the reaction in vivo could not be proven
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: wide substrate spectrum
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: wide substrate spectrum
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: wide substrate spectrum
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: final step in cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: last step in cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: terminal step in cholesterol de novo biosynthesis, pathway and physiological role, overview
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: terminal step in cholesterol de novo biosynthesis, physiological role, overview
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
349264, 349265, 349266, 349268, 349269, 349270, 349271, 349274, 349276, 349278, 349279, 656789, 656819 Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: isotope effects
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: i.e. 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-7-en-3beta-ol + NADPH
?
-
Substrates: i.e. lathosterol
Products: -
?
cholesta-7-en-3beta-ol + NADPH
?
-
Substrates: low activity
Products: -
?
cholesta-7-en-3beta-ol + NADPH
?
-
Substrates: not:
Products: -
?
cholesta-7-en-3beta-ol + NADPH
?
-
Substrates: i.e. lathosterol
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
-
Substrates: -
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
-
Substrates: -
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
-
Substrates: -
Products: -
?
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
Substrates: -
Products: -
?
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
Substrates: -
Products: -
?
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
Substrates: first committed step in biosynthesis of Caenorhabditis elegans bile acid-like steroids called dafachronic acids
Products: -
?
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
-
Substrates: -
Products: -
?
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
-
Substrates: -
Products: -
?
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
-
Substrates: i.e. ergosterol
Products: -
?
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
Substrates: i.e. ergosterol
Products: -
?
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
-
Substrates: i.e. ergosterol
Products: i.e. brassicasterol
?
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
-
Substrates: 25% activity of that with 7-dehydrocholesterol
Products: -
?
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
-
Substrates: i.e. ergosterol
Products: -
?
ergosta-5,7,22-trien-3beta-ol + NADPH
ergosta-5,22-diene-3beta-ol + NADP+
-
Substrates: enzyme activity diet-inducible: 2.6fold by 0.5% ergosterol and 5fold by 5.0% cholestyramine and 0.1% lovastatin
Products: -
?
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
-
Substrates: -
Products: -
?
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
Substrates: also ergosta-5,24(28)-, ergosta-5,22,24(28)-eneols and cholesta-5,24- or cholesta-5,22,24-eneols can be formed in vivo in the mutants of Saccharomyces cerevisiae
Products: -
?
ergosta-5,7-dienol + NADPH
ergosta-5-enol + NADP+
Substrates: -
Products: -
?
ergosta-5,7-dienol + NADPH
ergosta-5-enol + NADP+
Substrates: -
Products: -
?
additional information
?
-
-
Substrates: a mutational enzyme defect causes the Smith-Lemli-Opitz syndrome, a severe developmental disorder associated with multiple congenital anomalies, with low cholesterol and high precurosor 7-hydrocholesterol contents in plasma and tissues, clinical symptoms, overview
Products: -
?
additional information
?
-
-
Substrates: over 92% reduced enzyme activity, due to autosomal recessive mutational disorder, leads to the Smith-Lemli-Opitz syndrome in multiple cell types
Products: -
?
additional information
?
-
Substrates: reduced enzyme activity due to mutation leads to holoprosencephaly in vivo, phenotype
Products: -
?
additional information
?
-
-
Substrates: reduced enzyme activity due to mutation leads to holoprosencephaly in vivo, phenotype
Products: -
?
additional information
?
-
-
Substrates: several enzyme mutational defects cause the Smith-Lemli-Opitz syndrome, a severe developmental disorder associated with multiple congenital malformations and mental retardation, or desmosterolosis and lathosterolosis, rare autosomal recessive disorders, defect cholesterol synthesis, clinical symptoms, overview
Products: -
?
additional information
?
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing
Products: -
?
additional information
?
-
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing
Products: -
?
additional information
?
-
-
Substrates: enzyme is essential for steroidogenesis, enzyme is not regulated by the luteinizing hormone LH
Products: -
?
additional information
?
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing, enzyme is induced when sterols are depleted both in vivo and in vitro
Products: -
?
additional information
?
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing, enzyme is induced when sterols are depleted both in vivo and in vitro
Products: -
?
additional information
?
-
Substrates: no substrates: 8-dehydrocholesterol or 20S-hydroxylumisterol
Products: -
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
cholesterol + O2 + NAD(P)H + H+
cholesta-5,7-dien-3beta-ol + NAD(P)+ + 2 H2O
Substrates: first committed step in biosynthesis of Caenorhabditis elegans bile acid-like steroids called dafachronic acids
Products: -
?
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
additional information
?
-
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: terminal step in desmosterol de novo biosynthesis, pathway and physiological role, overview
Products: -
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: -
Products: -
?
7-dehydrodesmosterol + NADPH
desmosterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
Substrates: highly regiospecific for DELTA7-bond reduction, but wide substrate specificity
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: defect in cholesterol biosynthesis cause multiple congenital, developmental and morphogenic anomalies, e.g. the Smith-Lemli-Opitz syndrome due to a gene mutation, overview
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: cholesterol formation outside myelin sheath
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: reversibility of the reaction in vivo could not be proven
Products: -
?
cholesta-5,7-dien-3-beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: final step in cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: last step in cholesterol biosynthesis
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: terminal step in cholesterol de novo biosynthesis, pathway and physiological role, overview
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: terminal step in cholesterol de novo biosynthesis, physiological role, overview
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
-
Substrates: -
Products: -
?
cholesta-5,7-dien-3beta-ol + NADPH
cholesterol + NADP+
Substrates: enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
-
Substrates: -
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
-
Substrates: -
Products: -
?
cholesterol + NADP+
cholesta-5,7-dien-3beta-ol + NADPH + H+
-
Substrates: -
Products: -
?
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
-
Substrates: -
Products: -
?
desmosterol + NADP+
7-dehydrodesmosterol + NADPH + H+
-
Substrates: -
Products: -
?
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
-
Substrates: -
Products: -
?
ergosta-5,7-diene-3beta-ol + NADPH
ergosta-5-ene-3beta-ol + NADP+
Substrates: also ergosta-5,24(28)-, ergosta-5,22,24(28)-eneols and cholesta-5,24- or cholesta-5,22,24-eneols can be formed in vivo in the mutants of Saccharomyces cerevisiae
Products: -
?
additional information
?
-
-
Substrates: a mutational enzyme defect causes the Smith-Lemli-Opitz syndrome, a severe developmental disorder associated with multiple congenital anomalies, with low cholesterol and high precurosor 7-hydrocholesterol contents in plasma and tissues, clinical symptoms, overview
Products: -
?
additional information
?
-
-
Substrates: over 92% reduced enzyme activity, due to autosomal recessive mutational disorder, leads to the Smith-Lemli-Opitz syndrome in multiple cell types
Products: -
?
additional information
?
-
Substrates: reduced enzyme activity due to mutation leads to holoprosencephaly in vivo, phenotype
Products: -
?
additional information
?
-
-
Substrates: reduced enzyme activity due to mutation leads to holoprosencephaly in vivo, phenotype
Products: -
?
additional information
?
-
-
Substrates: several enzyme mutational defects cause the Smith-Lemli-Opitz syndrome, a severe developmental disorder associated with multiple congenital malformations and mental retardation, or desmosterolosis and lathosterolosis, rare autosomal recessive disorders, defect cholesterol synthesis, clinical symptoms, overview
Products: -
?
additional information
?
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing
Products: -
?
additional information
?
-
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing
Products: -
?
additional information
?
-
-
Substrates: enzyme is essential for steroidogenesis, enzyme is not regulated by the luteinizing hormone LH
Products: -
?
additional information
?
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing, enzyme is induced when sterols are depleted both in vivo and in vitro
Products: -
?
additional information
?
-
Substrates: enzyme is regulated through tissue-specific transcription and differential alternative splicing, enzyme is induced when sterols are depleted both in vivo and in vitro
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.